[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival]
{{output}}
Objective: To validate the Response to Ruxolitinib After 6 Months (RR6) prognostic model in Chinese patients with myelofibrosis (MF) treated with ruxolitinib and assess its incremental prognostic value when integrated with high molecular risk mutations (HMR(mt... ...
